ライフサイエンスコーパス: orthotopic

1 ug release of MMP9-DOX-NPs by 3.7-fold in an orthotopic 4T1 mammary adenocarcinoma mouse model.

2 f drug combinations in the highly aggressive orthotopic 4T1 murine breast cancer model.

3 The orthotopic 4T1 murine triple negative breast cancer mode

4 tively inhibits the growth of an aggressive, orthotopic 4T1 tumor model in vivo than free DOX and GEM

5 rmore, administration of SPHK1 inhibitors to orthotopic AML patient-derived xenografts reduced tumor

6 ian cancer and neuroblastoma in vitro and in orthotopic and metastatic xenograft mouse models, which

7 Pharmacological attenuation of LSD1 inhibits orthotopic and patient-derived HNSCC xenograft growth-sp

8 ot CARM-low, EOCs to PARP inhibitors in both orthotopic and patient-derived xenografts.

9 In orthotopic and syngeneic mouse models, silencing or inac

10 tatic progression of lung cancer cells in an orthotopic animal model.

11 red implants have shown promising results in orthotopic animal studies.

12 inally, we show that using an in vivo model, orthotopic basal-like tumors give significantly high pro

13 Using four orthotopic BC models, we show that mouse M-LECPs are sim

14 vivo studies in a galectin-expressing UMUC3 orthotopic BCa model to determine the ability of (18)F-l

15 pidly penetrate healthy brain parenchyma and orthotopic brain tumor tissues in rats.

16 togenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasis mouse model usi

17 greater anticancer efficacy in a murine 4T1 orthotopic breast cancer model than the currently used c

18 In an orthotopic breast cancer model, tumor-selective syntheti

19 Using an orthotopic breast cancer model, we showed that FN3-PARs

20 rvival in vitro and in growth restriction of orthotopic breast cancer xenografts in vivo.

21 hifted to earlier B-cell stages in mice with orthotopic breast cancer, spontaneous ovarian cancer, an

22 Animal studies using mice carrying orthotopic breast MDA-MB-231 tumors showed that the cycl

23 whole-tumor imaging data acquired from eight orthotopic breast tumor xenografts (i.e. a tumor 'ensemb

24 ineered to become capable of first homing to orthotopic breast tumors and then capturing angiogenin t

25 to generate in vivo mouse models containing orthotopic breast tumors for in vivo SPECT/MRI and biodi

26 gistically modulated the microenvironment of orthotopic breast tumors in mice, and significantly redu

27 G (d) (P = 0.002) and G (l) (P = 0.0006) in orthotopic breast tumors.

28 tumour eradication in about 50% of mice with orthotopic breast tumours.

29 osity (G (l)) were significantly greater for orthotopic BT-474 (G (d) = 5.9 +/- 0.2 kPa, G (l) = 4.7

30 Lung metastasis of orthotopic BT474-TtzmR xenografts was suppressed by the

31 In vivo activity in a highly aggressive orthotopic C6 glioma model demonstrated a greater than 2

32 CaP growth and shortened CR-CaP survival in orthotopic CaP xenografts.

33 Furthermore, using a rat syngeneic orthotopic CCA model, we found that HMC inhibited tumor

34 portant for following the natural history of orthotopic colon cancer and therapeutic efficacy.

35 s tumor burden in longitudinal monitoring of orthotopic colon cancer in this model as well as in othe

36 In this study, we have developed orthotopic colorectal cancer liver metastases (CRCLM) an

37 RT followed by IGF1R neutralization in orthotopic colorectal cancer models reduced the number o

38 Mice bearing orthotopic CT-2A or GL261 gliomas received POL5551 and/o

39 Our established orthotopic DCIS rat model was used to evaluate efficacy.

40 TAM inhibitors and PD-1 mAbs in a syngeneic orthotopic E0771 murine triple-negative breast cancer mo

41 Through the orthotopic engraftment of colon organoids we describe a

42 Orthotopic engraftment of the neural progenitor cells de

43 P < .001) of rat orthotopic esophageal cancers.

44 radable nanocarriers, and in vivo testing in orthotopic experimental gliomas.

45 delivered from the systemic circulation into orthotopic F98 gliomas using MRgFUS, where they elicited

46 improved survival time of nude mice bearing orthotopic GBM brain tumors.

47 miR-1300 led to decreased tumor growth in an orthotopic GBM model.

48 rvival when compared to control GBM cells in orthotopic GBM models.

49 y of miR-486-5p antagomirs to preestablished orthotopic GBM neurosphere-derived xenografts using adva

50 nanosystem was next evaluated in a validated orthotopic GBM nude mice model, studying the tumor growt

51 construct (chNKG2D) in fully immunocompetent orthotopic glioblastoma mouse models.

52 different in vivo tumor models, including an orthotopic glioblastoma xenograft model.

53 tecan as monotherapy for efficacy in a mouse orthotopic glioma model.

54 In an immunocompetent orthotopic glioma mouse model overexpressing truncated O

55 The combination inhibited orthotopic growth, VEGF-A expression, and tumor vasculat

56 In vivo cell depletion experiments in two orthotopic HCC mouse models as well as in vitro analysis

57 cells compared with the control group in an orthotopic head and neck squamous cell carcinoma (HNSCC)

58 re, we assessed a single-center cohort of 64 orthotopic heart transplant recipients transplanted betw

59 One patient had an orthotopic heart transplant, the second had a deceased d

60 2018 allocation policy change on outcomes of orthotopic heart transplantation (OHT) in patients bridg

61 reasing availability of circulatory support, orthotopic heart transplantation, and disease-specific t

62 ations used to prevent or treat rejection in orthotopic heart transplantation.

63 ding cells in vitro and in a patient-derived orthotopic hepatocellular carcinoma model in mice.

64 In an orthotopic HeyA8 tumor model of EOC, the Provector maint

65 Syngeneic and allogeneic orthotopic hindlimb transplantations were performed usin

66 CD154 mAb/rapamycin (RPM) induced long-term orthotopic hindlimb VCA survival (BALB/c->C57BL/6), as d

67 Using orthotopic HNSCC models, we show that radiation combined

68 inappropriately upregulated in HNSCC and an orthotopic HNSCC mouse model.

69 Mice bearing orthotopic human GBM tumors were administered a single d

70 deling the dense extracellular matrix in two orthotopic human ovarian carcinoma xenograft models.

71 two murine models of lung cancer, including orthotopic human xenograft and Kras(LSL/G12D) mouse mode

72 s assessed in vivo among 10 subcutaneous and orthotopic human xenograft models.

73 Importantly, examination of an orthotopic IDHmut tumor model showed that enhanced anima

74 and response to anti-PD-1 therapy using two orthotopic immunocompetent murine models of non-small ce

75 ls with MYCN, observing medulloblastoma upon orthotopic implantation in mice.

76 Here we show using a syngeneic orthotopic implantation model of pancreatic cancer that

77 Our in vivo studies with orthotopic implantation models demonstrated a robust inc

78 ing the hydrodynamic tail vein injection and orthotopic implantation models in vivo.

79 a significant decrease in tumor burden upon orthotopic implantation of MUC5AC-depleted pancreatic ca

80 nce in NADPH was seen between cervical tumor orthotopic implants in vivo, without a corresponding dif

81 n glioblastoma, the use of primary cells for orthotopic in vivo studies often requires large experime

82 ease in tumor growth in both heterotopic and orthotopic, including patient-derived xenograft, BC mode

83 lanoma lung colonization model (B16F10), and orthotopic injection of E0771 breast cancer cells to sho

84 These events were recapitulated by orthotopic injection of mutant FTE organoids.

85 Nude mice were given orthotopic injections of S2-007 cells, with or without (

86 rts of female Balb/C mice received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cel

87 approximately twofold longer survival in an orthotopic, isograft breast cancer mouse model.

88 Using an inducible orthotopic kidney tumor model, we demonstrate that YAP/T

89 Tirabrutinib treatment of mice bearing orthotopic Kras(G12D)-pancreatic lesions severely compro

90 uided delivery of a potent gene vector in an orthotopic large animal model of cartilage damage is rep

91 bles almost complete tumor suppression in an orthotopic liver cancer mouse model and ~1 month diabete

92 with liver disease clinically considered for orthotopic liver transplant for different indications we

93 erapy with neoadjuvant chemoradiotherapy and orthotopic liver transplant has emerged as a promising o

94 e patient successfully underwent a left-lobe orthotopic liver transplant; however, she developed a bi

95 Even though auxiliary partial orthotopic liver transplantation (APOLT) as a technique

96 cal decision-making and organ allocation for orthotopic liver transplantation (OLT) and was previousl

97 PV samples from IRI+ orthotopic liver transplantation (OLT) patients (n = 35)

98 njury and metabolic homeostasis, its role in orthotopic liver transplantation (OLT) remains elusive.

99 rative graft function in patients undergoing orthotopic liver transplantation (OLT).

100 patients with end-stage renal disease after orthotopic liver transplantation (OLT).

101 cute pulmonary and cardiac failure following orthotopic liver transplantation (OLT).

102 enase-1 (HO-1)-inducing regimens in clinical orthotopic liver transplantation (OLT).

103 tant causes of morbidity and mortality after orthotopic liver transplantation (OLT).

104 A patient on waitlist for orthotopic liver transplantation because of decompensate

105 s operation, making it a safe alternative to orthotopic liver transplantation for patients with a wid

106 After orthotopic liver transplantation, metformin precondition

107 rmothermic machine perfusion (NMP) and after orthotopic liver transplantation.

108 manipulations, ammonia scavenger drugs, and orthotopic liver transplantation.

109 One method for increasing the donor pool for orthotopic liver transplantations (OLTs) is to use uncon

110 g due to the released Mn(2+) , and inhibited orthotopic liver tumor growth via synergistic SDT/CDT.

111 4 inhibitor, which was effective in treating orthotopic liver tumors under obese/diabetic conditions.

112 m her son was implanted as auxiliary partial orthotopic LT.

113 /- 0.2 kPa, G (l) = 2.3 +/- 0.2 kPa, n = 7), orthotopic luc-D-212-MG (G (d) = 3.5 +/- 0.2 kPa, G (l)

114 ion can occur, but also introduces the mouse orthotopic lung transplant as a model for studying the i

115 005 to October 2018, 1234 patients underwent orthotopic lung transplantation at Duke University Hospi

116 the effect of targeted radiotherapy on human orthotopic lung tumors without influencing acute DNA dam

117 d metastasis to the lungs in a 4T1 syngeneic orthotopic mammary tumor model.

118 inhibition further reduced local invasion of orthotopic mammary tumors in vivo, and joint up-regulati

119 neoplastic tissues of mice and rats bearing orthotopic mammary tumors without observation of acute t

120 Upregulation of Mad1 accelerates growth of orthotopic mammary tumors, which show decreased levels o

121 rsus an uncoated control in mice bearing 4T1 orthotopic mammary tumors.

122 and 24 h after systemic administration into orthotopic MB tumor bearing NSG mice compared to non-tar

123 There was also significant decrease in the orthotopic MB tumor burden after systemic administration

124 Mice bearing orthotopic MDA-MB-231 breast cancer xenografts were imag

125 In vivo, lung metastases developing from orthotopic MDA-MB-231 tumors were reduced by 75% by miR-

126 In an orthotopic mice model of Neuroblastoma (NB) transplant,

127 44.7+/-4.8 % decrease of tumor burden in an orthotopic model of colon cancer via luciferase-positive

128 In an orthotopic model of glioblastoma, dendrimer-triptolide a

129 increase in per-tumor-cell uptake in a mouse orthotopic model of human triple-negative breast cancer.

130 (18)F]FHBG) of B7H3-sr39tk CAR T cells in an orthotopic model of osteosarcoma revealed tumor homing a

131 In an orthotopic model of osteosarcoma, DAC inhibited tumor gr

132 In an orthotopic model of skin SCC, genetic or pharmacological

133 , failed to promote tumorigenic growth in an orthotopic model.

134 future testing of cancer therapeutics in an orthotopic model.

135 BBB passage and tumor accumulation in a GBM orthotopic model.

136 le for further development and evaluation in orthotopic models of DIPG.

137 ion free survival in two clinically relevant orthotopic models of GBM resection and recurrence.

138 tient-derived cell lines, and in vivo, using orthotopic models of glioblastoma.

139 ly extended survival in mouse metastasis and orthotopic models of human colorectal cancer.

140 this association in multiple immunocompetent orthotopic models of lung cancer.

141 an GBM, and knockdown or knockout of APLN in orthotopic models of proneural or classical GBM subtypes

142 aneous sensory nerve transection in melanoma orthotopic models significantly decreased the rate of tu

143 reased production of its ligand Mst1, and in orthotopic models, suppression of Mst1 expression result

144 um of living tumor cells in subcutaneous and orthotopic models.

145 Moreover, using orthotopic mouse colon tumors estalished from human CRC

146 on studies and confirmed in subcutaneous and orthotopic mouse lung cancer models.

147 ficantly reduced tumor burden in a syngeneic orthotopic mouse model but also increased the sensitivit

148 myeloid cell recruitment to the lungs, in an orthotopic mouse model of breast cancer.

149 the developed method was demonstrated in an orthotopic mouse model of breast cancer.

150 treatment with a glycolytic inhibitor in an orthotopic mouse model of glioma.Materials and MethodsIn

151 significantly suppressing tumor growth in an orthotopic mouse model of HNSCC.

152 in human tumour xenografts in mice and in an orthotopic mouse model of human glioma.

153 er cells more sensitive to ferroptosis in an orthotopic mouse model of malignant mesothelioma.

154 gemcitabine directly into the pancreas in an orthotopic mouse model of pancreatic cancer.

155 In an orthotopic mouse model, after tumor establishment, athym

156 and caused potent tumor growth inhibition in orthotopic mouse model.

157 nsitivity both in cellular systems and in an orthotopic mouse model.

158 xenograft tumor growth and metastasis in an orthotopic mouse model.

159 oroglutamine compared with the kidney in the orthotopic mouse model.

160 Both subcutaneous and orthotopic mouse models have been extensively used in BB

161 Here, we use genetically engineered orthotopic mouse models of breast cancer to show that wh

162 eoadjuvant TSL HT combination therapy in two orthotopic mouse models of human breast cancer, MDA-MB-2

163 ribe a method for efficient establishment of orthotopic mouse models of patient-derived brain metasta

164 growth and cancer invasion in xenograft and orthotopic mouse models, respectively.

165 ploying inducible genetically engineered and orthotopic mouse models, we demonstrate a key role for t

166 d using cancer patient data, cell lines, and orthotopic mouse models.

167 sing serial single-cell RNA sequencing in an orthotopic mouse prostate cancer model, we find up-regul

168 survival through inhibition of YAP/TAZ in an orthotopic mouse xenograft model.

169 growth and increases overall survival in an orthotopic mouse xenograft model.

170 In an orthotopic murine breast cancer model, pHLIP-targeted op

171 When applied to an orthotopic murine glioblastoma xenograft model, SM-OCT r

172 etail the application of our framework to an orthotopic murine glioma (GL261) and a human colorectal

173 An orthotopic murine model of lung transplant using lymphat

174 In an orthotopic murine model of pancreatic cancer, AES-135 pr

175 We utilized an optimized orthotopic murine osteosarcoma model and human osteosarc

176 Using the orthotopic murine Panc02 model of PDAC, we show that sys

177 onist (177)Lu-DOTA-JR11 longitudinally in an orthotopic murine pancreatic neuroendocrine neoplasm mod

178 BTIC in human glioblastoma specimens and in orthotopic murine xenografts of human BTIC implanted int

179 tended survival of mice with drug-resistant, orthotopic NB and it caused long-term (6+ months) remiss

180 splantable, carcinogen- or oncogene induced) orthotopic NSCLC models.

181 synergistically enhance tumor regression in orthotopic NSCLC mouse model.

182 three-dimensional culture and in an in vivo orthotopic nude mouse model of HNSCC through a novel tra

183 ancer models for drug discovery are based on orthotopic or subcutaneous tumours.

184 ntum is a prerequisite premetastatic step in orthotopic ovarian cancer models.

185 CPM-BIDEN-AP significantly reduced growth of orthotopic ovarian tumors, with CCPM-BIDEN-AP displaying

186 Treatment of orthotopic pancreatic tumor-bearing mice with gemcitabin

187 LDC loaded NPs at the dose of 20 mg/kg into orthotopic pancreatic tumor-bearing NSG mice every alter

188 Knockdown of PAF1 reduces the ability of orthotopic pancreatic tumors to develop and progress in

189 Nude mice with orthotopic pancreatic tumors were randomly assigned into

190 , and significantly extended the survival of orthotopic pancreatic tumour-bearing mice compared to th

191 tumour ILC2s (TILC2s) and CD8(+) T cells in orthotopic pancreatic tumours but not heterotopic skin t

192 we performed an in vivo CRISPR screen in an orthotopic patient-derived xenograft (PDX) model to iden

193 tiates the effects of radiation in flank and orthotopic patient-derived xenograft models of GBM.

194 To test this, we assembled a panel of orthotopic patient-derived xenografts (PDX) and subjecte

195 sease, here we develop a protocol to produce orthotopic patient-derived xenografts at diagnosis, recu

196 biological parameters using subcutaneous and orthotopic PC-3 xenografts.

197 se like-2 (anti-LOXL2) antibody in syngeneic orthotopic PDA mouse models significantly decreased matr

198 Using patient samples and orthotopic PDAC biological models, we showed that radiot

199 significantly prolongs survival in a murine orthotopic PDAC model with a long-term memory immune res

200 In a KRAS-induced orthotopic PDAC model, coadministration of iRGD enhanced

201 In murine orthotopic PDAC models, pancreatic tumor growth was dela

202 ith synergistic efficacy in subcutaneous and orthotopic PDAC mouse models.

203 jection or intravenous biodistribution to an orthotopic PDAC site.

204 ive PDAC therapies, we leveraged a syngeneic orthotopic PDAC transplant mouse model to perform a larg

205 d time-effective way to monitor heterogenous orthotopic PDX growth.

206 In orthotopic phosphatase and tensin homologue (PTEN)-defic

207 ination of endogenous TCR chains and for the orthotopic placement of TCRs in human T cells.

208 The uterus was transplanted in orthotopic position with vascular anastomoses to the ext

209 GBMs using both in vitro assays and in vivo orthotopic preclinical models.

210 In vivo, using an orthotopic prostate cancer mouse model and a transgenic

211 g widespread transgene expression throughout orthotopic rat brain tumors in vivo following administra

212 In vivo, using a clinically relevant orthotopic resection model of primary glioblastoma and e

213 cooperate, we used intravital microscopy of orthotopic sarcoma and melanoma xenografts.

214 ng the lifespan of the mice in an aggressive orthotopic stem cell-like GBM that recapitulates the his

215 CpG-1826 (Lys-Mix) in both Py230 and Py8119 orthotopic syngeneic mouse models of TNBC.

216 or growth and spontaneous lung metastasis in orthotopic syngeneic TNBC mouse models.

217 neal implantation of nanotextile implants in orthotopic, syngeneic ID8-VEGF tumor-bearing C57BL/6 mic

218 In vivo, CFI-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent

219 ting of alpha- and beta-chains combined with orthotopic TCR placement leads to accurate alphabeta-pai

220 tol MRI showed 136% +/- 88 greater uptake in orthotopic thyroid tumors compared with pulmonary lesion

221 Results TAM levels were higher in orthotopic thyroid tumors compared with pulmonary metast

222 In an orthotopic TNBC model, we have shown that systemically a

223 influence on the microvascular integrity of orthotopic tracheal allografts as an anatomic basis for

224 An orthotopic tracheal transplantation model further evalua

225 cing schwannoma formation in a novel in vivo orthotopic transplant model.

226 with pharmacologic inhibition approaches in orthotopic transplantation and patient-derived xenograft

227 ses metastasis in intracardial xenograft and orthotopic transplantation models, and correlates with p

228 ted GSC self-renewal and tumor initiation in orthotopic transplantation models.

229 Orthotopic transplantation of NES cells generated from G

230 vitro and produce more metastatic lesions in orthotopic transplants than Coronin 1C-reexpressing cell

231 Elevated levels of PDGFB accelerated orthotopic tumor growth and intracranial growth of mamma

232 ere injected into wild-type littermates, and orthotopic tumor growth and metastasis were monitored.

233 CC cell proliferation in vitro and inhibited orthotopic tumor growth in vivo.

234 t thyroid lobe of athymic nude mice, and the orthotopic tumor growth was monitored via ultrasound and

235 man and mouse breast cancer cells, decreased orthotopic tumor growth, reduced tumor angiogenesis and

236 rative competency in the brain, with reduced orthotopic tumor growth.

237 ivo in U87MG GBM and radio/TMZ-resistant GBM orthotopic tumor models.

238 n-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models.

239 Here, using multiple orthotopic tumor mouse models resistant to anti-PD-L1-th

240 Of note, the transgene expression within the orthotopic tumor tissue occurred preferentially in gliom

241 aller and fewer tumor spheres in culture and orthotopic tumors and metastases in mice.

242 spectively, which were expressed by cells in orthotopic tumors and PDAC specimens from patients.

243 tention of the DART nanoparticles within the orthotopic tumors compared to non-targeted versions.

244 Induced expression of MBNL1 in established orthotopic tumors dramatically inhibited tumor progressi

245 Furthermore, KPC orthotopic tumors from mice given the combination contai

246 Mice with orthotopic tumors given the combination of anti-PD-1 and

247 R172H/+);Pdx-1-Cre (KPC) mice, and mice with orthotopic tumors grown from Panc02 cells, Kras(G12D);P5

248 compared to the subcutaneous model the PC-3 orthotopic tumors had significantly higher levels of per

249 etic resonance imaging (MRI) for quantifying orthotopic tumors in a mouse model of colon cancer.

250 These cells were grown as orthotopic tumors in athymic nude mice and PAF1 knockdow

251 rming activities in culture and formation of orthotopic tumors in mice.

252 red with control cells, and slowed growth of orthotopic tumors in mice.

253 or CXCL10, or their receptors, in mice with orthotopic tumors significantly reduced nociceptive hype

254 Mice with orthotopic tumors that were given the combination of ant

255 Orthotopic tumors were grown from K8484 cells in mice, a

256 re tumor-free 100 days after implantation of orthotopic tumors were rechallenged with PDAC cells (KPC

257 diotracer in galectin-1-overexpressing UMUC3 orthotopic tumors when imaged with PET.

258 In mice with orthotopic tumors, all those given control antibody or a

259 ceptors reduce hypersensitivity in mice with orthotopic tumors, and patients with PDACs with high lev

260 In orthotopic tumors, CycT decreases the levels of proteins

261 xtended survival of mice bearing GSC-derived orthotopic tumors, irrespective of PARPi-sensitivity.

262 mice through intrathyroid injection to model orthotopic tumors, or intravenously to model hematogenou

263 Orthotopic tumour mouse models are increasingly being us

264 Nude rats bearing orthotopic U87 glioblastoma and healthy controls were in

265 perpolarized [1-(13)C]-pyruvate on mice with orthotopic U87MG glioma and healthy control mice.

266 In an orthotopic Wnt reporter model, Wnt(hi) GBM cells (which

267 concept, in subtype-specific patient-derived orthotopic xenograft (PDOX) mice, Classical-subtype demo

268 ed survival in syngeneic and patient-derived orthotopic xenograft (PDOX) mouse models of GBM.

269 t study established a unique patient-derived orthotopic xenograft (PDOX) nude mouse model of a highly

270 In orthotopic xenograft animal model, TMPRSS2 overexpressio

271 Compared with orthotopic xenograft assays, the novel biomaterial cultu

272 antly inhibits tumor growth in vivo using an orthotopic xenograft breast mouse model.

273 ricular administration of the Lck-I using an orthotopic xenograft glioma model, results in statistica

274 uired for TNBC tumor growth in vivo using an orthotopic xenograft model in immunocompromised mice.

275 In an orthotopic xenograft model, TICs stably transduced with

276 n both ovarian cancer cell lines and a mouse orthotopic xenograft model.

277 e-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.

278 e cell lines, and prolonged survival in both orthotopic xenograft models and mouse models of primary

279 In orthotopic xenograft models of pancreatic cancer, combin

280 vitro and in vivo, and prolongs survival in orthotopic xenograft models.

281 rew faster than wild-type clones in s.c. and orthotopic xenograft models.

282 ovel oligodendroglioma patient tumor-derived orthotopic xenograft mouse models and cell lines to veri

283 om RNA sequencing from patient derived mouse orthotopic xenograft samples.

284 -negative breast cancer, and patient-derived orthotopic xenografts (PDX) of human glioblastoma.

285 on drives the evolution of the GSC-initiated orthotopic xenografts and suggest that radiation-driven

286 Brain tumor-initiating cells (BTICs) and orthotopic xenografts are widely used in investigating G

287 Compared with CD47 wild-type xenografts, orthotopic xenografts derived from CD47(-/-) tumor cells

288 Toward this end, orthotopic xenografts grown in nude mice were exposed to

289 otherapy to influence GBM evolution, we used orthotopic xenografts initiated from CD133(+) GBM stem-l

290 stomas (NB) in transgenic TH-MYCN mice; (ii) orthotopic xenografts of a drug-resistant NB line SK-N-B

291 as validated by oral administration of 27 in orthotopic xenografts of endocrine-resistant breast canc

292 and monitor tumor burden in patient-derived orthotopic xenografts of glioblastoma.

293 ical study using an in vivo mouse model with orthotopic xenografts of HCC cells confirmed the in vitr

294 Orthotopic xenografts of MKN45/5FU cells in the stomach

295 to the 5-FU dose, and in gastric submucosal orthotopic xenografts of MKN45/5FU cells.

296 le-negative breast cancer cells implanted as orthotopic xenografts, loss of G6PD modestly decreased p

297 a cell proliferation in vitro, as well as in orthotopic xenografts.

298 ost survival compared with untreated GSCs in orthotopic xenografts.

299 diation drives the evolution of glioblastoma orthotopic xenografts; when translated to the clinic, th

300 Finally, in an orthotopic zebrafish model of retinoblastoma, a 55% decr